About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Press Releases 2021
Biocon Biologics
/
News – Posts
/
Press Releases
/
Press Releases 2021
Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
Thu, 30-Dec-2021
Posted by: Biocon Biologics
No Comments
Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
Thu, 23-Dec-2021
Posted by: Biocon Biologics
No Comments
Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
Wed, 01-Dec-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
Fri, 19-Nov-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
Tue, 16-Nov-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
Mon, 15-Nov-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies
Thu, 04-Nov-2021
Posted by: Biocon Biologics
No Comments
Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;
Fri, 22-Oct-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
Thu, 21-Oct-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
Thu, 16-Sep-2021
Posted by: Biocon Biologics
No Comments
1
2
3